Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q2 2020 · 10-Q
Revenue$0.00$0.00no prior Q2 2019 on file Net Income-$17.42M-$17.42MN/M vs Q2 2019 EPS Diluted-$4.12-$4.12N/M vs Q2 2019 Operating Income-$1,558,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
derived
ended Jun 30, 2020 · filed Aug 14, 2020 · 45 d after period end